Sino Biopharmaceutical Management

Management criteria checks 2/4

Sino Biopharmaceutical's CEO is Eric S. Y. Tse, appointed in Jul 2022, has a tenure of 1.75 years. directly owns 22.11% of the company’s shares, worth $1.43B. The average tenure of the management team and the board of directors is 1.3 years and 9 years respectively.

Key information

Eric S. Y. Tse

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.8yrs
CEO ownership	22.1%
Management average tenure	1.3yrs
Board average tenure	9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Eric S. Y. Tse's remuneration changed compared to Sino Biopharmaceutical's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	n/a	n/a	CN¥3b
Sep 30 2022	n/a	n/a	CN¥5b
Jun 30 2022	n/a	n/a	CN¥8b
Mar 31 2022	n/a	n/a	CN¥14b
Dec 31 2021	CN¥23m	CN¥6m	CN¥15b
Sep 30 2021	n/a	n/a	CN¥12b
Jun 30 2021	n/a	n/a	CN¥10b
Mar 31 2021	n/a	n/a	CN¥4b
Dec 31 2020	CN¥25m	CN¥7m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥3b
Mar 31 2020	n/a	n/a	CN¥3b
Dec 31 2019	CN¥6m	CN¥870k	CN¥3b

Compensation vs Market: Insufficient data to establish whether Eric S. Y.'s total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Eric S. Y.'s compensation has been consistent with company performance over the past year.

CEO

Eric S. Y. Tse (27 yo)

1.8yrs

Tenure

CN¥23,092,000

Compensation

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Y. Y. Tse	Executive Chairwoman of the Board	8.8yrs	CN¥39.66m	0.033% CN¥ 2.1m
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7yrs	CN¥35.18m	16.19% CN¥ 1.1b
Mingqin Li	Senior VP & Executive Director	no data	CN¥1.20m	no data
Zhoushan Tian	Executive Director	no data	CN¥1.87m	no data
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.03m	1.95% CN¥ 126.5m
Eric S. Y. Tse	CEO & Executive Director	1.8yrs	CN¥23.09m	22.11% CN¥ 1.4b
Ping Tse	Founder & Senior Executive Vice Chairman	3.7yrs	CN¥41.92m	9.12% CN¥ 591.9m
Chun Ling Li	Chief Financial Officer	1.3yrs	no data	no data
Sean Chen	Chief Strategy Officer	1.3yrs	no data	no data
Orphanides George	Chief Scientific Advisor of invoX	1.3yrs	no data	no data
Chau Ling Yu	Assistant VP & Financial Controller	no data	no data	no data
Toogood Ben	CEO of invoX & Head of Globalization	1.3yrs	no data	no data

1.3yrs

Average Tenure

54yo

Average Age

Experienced Management: SBMF.F's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Y. Y. Tse	Executive Chairwoman of the Board	8.8yrs	CN¥39.66m	0.033% CN¥ 2.1m
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7yrs	CN¥35.18m	16.19% CN¥ 1.1b
Mingqin Li	Senior VP & Executive Director	9yrs	CN¥1.20m	no data
Zhoushan Tian	Executive Director	9yrs	CN¥1.87m	no data
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.03m	1.95% CN¥ 126.5m
Eric S. Y. Tse	CEO & Executive Director	4.5yrs	CN¥23.09m	22.11% CN¥ 1.4b
Ping Tse	Founder & Senior Executive Vice Chairman	3.7yrs	CN¥41.92m	9.12% CN¥ 591.9m
Zhengfei Lu	Independent Non-Executive Director	18.4yrs	CN¥340.00k	no data
Dakui Li	Independent Non-Executive Director	19.6yrs	CN¥352.00k	no data
Lu Fu Zhang	Independent Non-Executive Director	9yrs	CN¥340.00k	no data
Hong Lu	Independent Non-Executive Director	9yrs	CN¥320.00k	no data
Kwok Tung Li	Independent Non-Executive Director	3.3yrs	CN¥340.00k	0.00039% CN¥ 25.3k

9.0yrs

Average Tenure

59.5yo

Average Age

Experienced Board: SBMF.F's board of directors are considered experienced (9 years average tenure).

Sino Biopharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022

Sino Biopharmaceutical Limited Appoints Li Kwok Tung Donald as an Independent Non-Executive Director and a Member of the Audit Committee and Nomination Committee

Sino Biopharmaceutical Limited Announces Management Changes

Recent updates

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule

Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial

Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139"

Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial

Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication

Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE

Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022

Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHND5071 Obtained Approval for Clinical Trial

Sino Biopharmaceutical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing

Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate Granted by National Medical Products Administration

Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial

Akeso, Inc. and Sino Biopharmaceutical Limited Announces Penpulimab Monoclonal Antibody Marketing Approval in China

Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injection" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Announces That the Phase Iii Clinical Trial Results of "Anlotinib Hydrochloride Capsules

Sino Biopharmaceutical Limited Announces "Tolvaptan Tablets" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Announces "Sunitinib Malate Capsules" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Declares Dividend for the Three Months Ended 31 March, 2021, Payable on 12 July, 2021

Sino Biopharmaceutical Limited Announces "Decitabine for Injection" Passes Consistency Evaluation

Sino Biopharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

Akeso, Inc. and Sino Biopharmaceutical Limited Announce the Interim Analysis of the Phase III Clinical Trial of Penpulimab

Sino Biopharmaceutical Limited Announces Alfacalcidol Soft Capsule Obtains the Notice of Approval of Supplemental Application on Pharmaceutical Product Issued by the National Medical Products Administration of the People's Republic of China

Sino Biopharmaceutical Limited Announces "Esomeprazole Magnesium Enteric-Coated Capsules" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Announces Passing of Consistency Evaluation for Bortezomib for Injection

Akeso, Inc. and Sino Biopharmaceutical Limited Announces Latest Study of Penpulimab Monoclonal Antibody (PD-1) in Combination with Anlotinib for 1L Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Passing of Consistency Evaluation for "Linezolid and Glucose Injection"

Sino Biopharmaceutical Limited Obtains Drug Registration Certificate for Afatinib Dimaleate Tablets

Sino Biopharmaceutical Limited Appoints Li Kwok Tung Donald as an Independent Non-Executive Director and a Member of the Audit Committee and Nomination Committee

Sino Biopharmaceutical Limited's Digestive System Medicine Pantoprazole Sodium for Injection Obtains the Notice of Approval of Supplemental Applications Issued by the National Medical Products Administration of the People's Republic of China

Sino Biopharmaceutical Limited Announces Pomalidomide Capsules Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited to Report Q3, 2020 Results on Nov 30, 2020

Sino Biopharmaceutical Limited Announces Completion of Enrollment in Phase Iii Clinical Trial in Combination with Chemotherapy for 1L Metastatic Squamous Nsclc with Penpulimab

Sino Biopharmaceutical Limited Announces Management Changes

Sino Biopharmaceutical Limited to Report First Half, 2020 Results on Aug 28, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure